| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 142.31% | HC Wainwright & Co. | $58 → $52 | Maintains | Buy |
| 11/09/2023 | 170.27% | HC Wainwright & Co. | $66 → $58 | Maintains | Buy |
| 08/24/2023 | 207.55% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
| 08/07/2023 | 207.55% | HC Wainwright & Co. | $105 → $66 | Maintains | Buy |
| 07/20/2023 | 128.33% | Goldman Sachs | $43 → $49 | Maintains | Buy |
| 06/06/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | Buy → Buy |
| 05/05/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
| 04/28/2023 | 91.05% | Barclays | $55 → $41 | Maintains | Overweight |
| 04/20/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
| 03/07/2023 | 165.61% | JP Morgan | $53 → $57 | Maintains | Overweight |
| 03/07/2023 | 389.28% | HC Wainwright & Co. | $99 → $105 | Maintains | Buy |
| 01/26/2023 | 109.69% | Goldman Sachs | $40 → $45 | Maintains | Buy |
| 12/01/2022 | 109.69% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 11/04/2022 | 361.32% | HC Wainwright & Co. | $103 → $99 | Maintains | Buy |
| 10/21/2022 | 105.03% | Goldman Sachs | $51 → $44 | Maintains | Buy |
| 09/12/2022 | 379.96% | HC Wainwright & Co. | $94 → $103 | Maintains | Buy |
| 08/09/2022 | 338.02% | HC Wainwright & Co. | $95 → $94 | Maintains | Buy |
| 06/06/2022 | 342.68% | HC Wainwright & Co. | $142 → $95 | Maintains | Buy |
| 05/27/2022 | 132.99% | Wedbush | $110 → $50 | Maintains | Outperform |
| 05/24/2022 | 282.11% | Goldman Sachs | $76 → $82 | Maintains | Buy |
| 09/08/2021 | 389.28% | JP Morgan | $97 → $105 | Maintains | Overweight |
| 08/05/2021 | 538.4% | HC Wainwright & Co. | $136 → $137 | Maintains | Buy |
| 07/21/2021 | 533.74% | HC Wainwright & Co. | $124 → $136 | Maintains | Buy |
| 03/22/2021 | 421.9% | Goldman Sachs | → $112 | Assumes | → Buy |
| 02/25/2021 | 477.82% | HC Wainwright & Co. | $101 → $124 | Maintains | Buy |
| 01/22/2021 | 328.7% | Barclays | $83 → $92 | Maintains | Overweight |
| 01/19/2021 | 370.64% | HC Wainwright & Co. | $87 → $101 | Maintains | Buy |
| 12/28/2020 | 305.41% | HC Wainwright & Co. | $73 → $87 | Reiterates | → Buy |
| 10/29/2020 | 240.17% | HC Wainwright & Co. | $58 → $73 | Maintains | Buy |
| 08/13/2020 | 132.99% | Wedbush | $48 → $50 | Maintains | Outperform |
| 05/13/2020 | 123.67% | Wedbush | $45 → $48 | Maintains | Outperform |
| 05/05/2020 | 123.67% | Barclays | → $48 | Initiates Coverage On | → Overweight |
| 04/14/2020 | 170.27% | HC Wainwright & Co. | $60 → $58 | Maintains | Buy |
| 03/19/2020 | 179.59% | HC Wainwright & Co. | $40 → $60 | Upgrades | Neutral → Buy |
| 03/04/2020 | 86.39% | HC Wainwright & Co. | → $40 | Downgrades | Buy → Neutral |
| 01/21/2020 | 86.39% | HC Wainwright & Co. | $34 → $40 | Maintains | Buy |
| 12/04/2019 | 53.77% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 10/08/2019 | 49.11% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/08/2019 | 53.77% | Wedbush | → $33 | Initiates Coverage On | → Outperform |
| 10/08/2019 | 72.41% | Goldman Sachs | → $37 | Initiates Coverage On | → Buy |
What is the target price for SpringWorks Therapeutics (SWTX)?
The latest price target for SpringWorks Therapeutics (NASDAQ: SWTX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $52.00 expecting SWTX to rise to within 12 months (a possible 142.31% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for SpringWorks Therapeutics (SWTX)?
The latest analyst rating for SpringWorks Therapeutics (NASDAQ: SWTX) was provided by HC Wainwright & Co., and SpringWorks Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for SpringWorks Therapeutics (SWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating SpringWorks Therapeutics (SWTX) correct?
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $58.00 to $52.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $21.46, which is out of the analyst's predicted range.